![]() |
|
|
Vol. 301, Issue 2, 586-593, May 2002
Division of Pharmaceutical Sciences, College of Pharmacy,
University of Michigan, Ann Arbor, Michigan (L.Y.L., G.L.A., T.H.,
F.K., J.T.T., D.F.); and TSRL, Inc., Ann Arbor, Michigan (J.S.K.)
The purpose of this study was to investigate transport and
metabolism contributions to low indinavir permeability in rat ileum and
enhanced drug permeability in the jejunum. Permeability models utilized
included single pass in situ rat intestinal perfusion and rat
intestinal tissue mounted in Ussing chambers. Intestinal metabolism was
measured by fractional appearance of metabolite (Fmet), determined as the percentage of the
predominant metabolite M6 over luminal loss of indinavir in the
perfusion model. Among the results, indinavir exhibited bidirectional
transport across rat ileum. Verapamil and cyclosporin A inhibited net
flux by 37 and 38%, respectively. Intestinal metabolism of indinavir
was most significant in upper jejunum
(Fmet = 65.78 ± 19.02%),
decreasing in midjejunum (Fmet = 31.58 ± 5.63%). M6 was not detectable in ileum or colon. Western
blot analysis of rat intestinal mucosal tissue samples confirmed that
the axial expression of CYP3A was consistent with the regional pattern
of formation of M6. Intestinal metabolism was saturable and could be
inhibited by the CYP3A inhibitor, ketoconazole. A low luminal
concentration of indinavir (1 µM) was associated with high
Fmet (87.90 ± 14.30%), whereas a high luminal concentration of indinavir (50 µM) was associated with low
Fmet (35.84 ± 11.59%). In the
presence of ketoconazole, both Fmet and
permeability of indinavir were reduced in the jejunum. These results
suggest that 1) intracellular metabolism of indinavir enhances apical
uptake of indinavir in the rat jejunum as a function of the increased
concentration gradient generated across the epithelial cell membrane
and 2) the efflux transporter P-glycoprotein limits apical uptake of
indinavir in the ileum, resulting in low apparent permeability.
This article has been cited by other articles:
![]() |
T. Nishimura, N. Amano, Y. Kubo, M. Ono, Y. Kato, H. Fujita, Y. Kimura, and A. Tsuji Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey Drug Metab. Dispos., August 1, 2007; 35(8): 1275 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Pang MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES) Drug Metab. Dispos., December 1, 2003; 31(12): 1507 - 1519. [Full Text] [PDF] |
||||
![]() |
D. Tam, H. Sun, and K. S. Pang INFLUENCE OF P-GLYCOPROTEIN, TRANSFER CLEARANCES, AND DRUG BINDING ON INTESTINAL METABOLISM IN CACO-2 CELL MONOLAYERS OR MEMBRANE PREPARATIONS: A THEORETICAL ANALYSIS Drug Metab. Dispos., October 1, 2003; 31(10): 1214 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tam, R. G. Tirona, and K. S. Pang Segmental Intestinal Transporters and Metabolic Enzymes on Intestinal Drug Absorption Drug Metab. Dispos., April 1, 2003; 31(4): 373 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Cummins, L. Salphati, M. J. Reid, and L. Z. Benet In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 306 - 314. [Abstract] [Full Text] |
||||
![]() |
P. S. Burton, J. T. Goodwin, T. J. Vidmar, and B. M. Amore Predicting Drug Absorption: How Nature Made It a Difficult Problem J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 889 - 895. [Abstract] [Full Text] [PDF] |
||||